利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.025 秒)

    Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
    2.
    发明公开
    Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use 有权
    IL-17A-，IL-17F-和IL-23P19-拮抗剂和Verwendungsverfahren

    公开(公告)号：EP2392597A2

    公开(公告)日：2011-12-07

    申请号：EP11168730.7

    申请日：2008-04-28

    申请人： ZymoGenetics, Inc.

    发明人： Lewis, Katherine E. ,  Presnell, Scott R. ,  Levin, Steven D.

    IPC分类号： C07K16/24 ,  A61K39/395 ,  C07K16/46 ,  A61P37/06

    CPC分类号： C07K16/244 ,  A61K2039/507 ,  C07K2317/31 ,  C07K2317/56

    摘要： There is provided an antagonist of IL-23 and of IL-17A or IL-17F comprising: (i) an antibody or antibody fragment that binds the p19 subunit of IL-23 as shown in SEQ ID NO: 4; and (ii) an antibody or antibody fragment that binds IL-17A as shown in SEQ ID NO: 2 or that binds IL-17F as shown in SEQ ID NO: 6; wherein the antibody or antibody fragment that binds IL-17A or IL-17F comprises a HCDR1 amino acid sequence, a HCDR2 amino acid sequence, and a HCDR3 amino acid sequence of the variable heavy region selected from the group consisting of the variable heavy region of the hybridoma of ATCC Patent Deposit Designation PTA-7988; and wherein the variable light region comprises a LCDR1 amino acid sequence, a LCDR2 amino acid sequence, and a LCDR3 amino acid sequence of the variable light region of the hybridoma of ATCC Patent Deposit Designation PTA-7988.

    摘要翻译： 提供了IL-23和IL-17A或IL-17F的拮抗剂，其包含：（i）结合SEQ ID NO：4所示的IL-23的p19亚基的抗体或抗体片段; 和（ii）如SEQ ID NO：2所示结合IL-17A或者如SEQ ID NO：6所示结合IL-17F的抗体或抗体片段; 其中结合IL-17A或IL-17F的抗体或抗体片段包含可变重区的HCDR1氨基酸序列，HCDR2氨基酸序列和HCDR3氨基酸序列，所述HCDR1氨基酸序列选自下组： ATCC专利保藏号PTA-7988的杂交瘤; 并且其中所述可变光区域包含ATCC专利保藏号PTA-7988的杂交瘤的可变光区的LCDR1氨基酸序列，LCDR2氨基酸序列和LCDR3氨基酸序列。

    Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
    6.
    发明公开
    Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use 有权
    IL-17A，IL-17F-和IL-23p19的拮抗剂及其使用方法

    公开(公告)号：EP2392597A3

    公开(公告)日：2012-03-07

    申请号：EP11168730.7

    申请日：2008-04-28

    申请人： ZymoGenetics, Inc.

    发明人： Lewis, Katherine E. ,  Presnell, Scott R. ,  Levin, Steven D.

    IPC分类号： C07K16/24 ,  A61K39/395 ,  C07K16/46 ,  A61P37/06

    CPC分类号： C07K16/244 ,  A61K2039/507 ,  C07K2317/31 ,  C07K2317/56

    摘要： There is provided an antagonist of IL-23 and of IL-17A or IL-17F comprising: (i) an antibody or antibody fragment that binds the p19 subunit of IL-23 as shown in SEQ ID NO: 4; and (ii) an antibody or antibody fragment that binds IL-17A as shown in SEQ ID NO: 2 or that binds IL-17F as shown in SEQ ID NO: 6; wherein the antibody or antibody fragment that binds IL-17A or IL-17F comprises a HCDR1 amino acid sequence, a HCDR2 amino acid sequence, and a HCDR3 amino acid sequence of the variable heavy region selected from the group consisting of the variable heavy region of the hybridoma of ATCC Patent Deposit Designation PTA-7988; and wherein the variable light region comprises a LCDR1 amino acid sequence, a LCDR2 amino acid sequence, and a LCDR3 amino acid sequence of the variable light region of the hybridoma of ATCC Patent Deposit Designation PTA-7988.

    Soluble zalpha11 cytokine receptors
    7.
    发明公开
    Soluble zalpha11 cytokine receptors 有权
    可溶性zalpha11细胞因子受体

    公开(公告)号：EP1749888A3

    公开(公告)日：2007-03-14

    申请号：EP06011463.4

    申请日：2001-04-03

    申请人： ZymoGenetics, Inc.

    发明人： Sprecher, Cindy A. ,  Novak, Julia E. ,  West, James, W. ,  Presnell, Scott R. ,  Holly, Richard D. ,  Nelson, Andrew J.

    IPC分类号： C12N15/12 ,  C12N15/62 ,  C12N5/10 ,  C07K14/715 ,  C07K16/28 ,  A61K38/19

    CPC分类号： C07K16/2866 ,  A61K38/00 ,  C07K14/7155 ,  C07K2317/73 ,  C07K2319/00

    摘要： Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zalpha11 receptors that may be used as novel cytokine antagonist, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block zalpha11 Ligand activity in vitro and in vivo, and may be used in conjunction with zalpha11 Ligand and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

    摘要翻译： 新型多肽组合，编码多肽的多核苷酸以及相关组合物和方法公开用于可用作新型细胞因子拮抗剂的可溶性zalpha11受体，并且在用于检测刺激造血细胞，淋巴细胞和骨髓细胞的增殖和/或发育的配体的方法内 在体外和体内。 配体结合受体多肽也可以用于在体外和体内阻断zalpha11配体活性，并且可以与zalpha11配体和其他细胞因子一起使用以选择性刺激免疫系统。 本发明还包括生产蛋白质的方法，其用途和抗体。